Research programme: bradykinin B1 receptor antagonists - Merck

Drug Profile

Research programme: bradykinin B1 receptor antagonists - Merck

Latest Information Update: 26 Aug 2011

Price : $50

At a glance

  • Originator Merck & Co
  • Class Small molecules
  • Mechanism of Action Bradykinin B1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Pain

Most Recent Events

  • 26 Aug 2011 No development reported - Preclinical for Inflammation in USA (PO)
  • 26 Aug 2011 No development reported - Preclinical for Pain in USA (PO)
  • 18 Jul 2007 Preclinical data added to the Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top